Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

Published:2019-09 Issue:9 Volume:30 Page:1448-1459
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hofman P.^ORCID,Heeke S.,Alix-Panabières C.,Pantel K.

Funder

Association de Recherche contre le Cancer

ARC

Ligue Départementale 06 de Lutte contre le Cancer

Conseil Départemental 06

Cancéropôle PACA

French Government

National Research Agency

European Union’s Seventh Framework Program

European Liquid Biopsies Academy

ELBA

Innovative Training Networks (ITN) Horizon 2020 project

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz196/28941052/mdz196.pdf

Reference147 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

2. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018

4. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial;Patel;Lancet Oncol,2018

5. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma;Powles;JAMA Oncol,2017

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated serum soluble programmed death ligand 1 (sPD-L1) level correlate with clinical characteristics in breast cancer patients: A study at Hospital Universiti Sains Malaysia;Cytokine;2024-10

2. Identification of a proteomic signature for predicting immunotherapy response in patients with metastatic non-small cell lung cancer;Molecular & Cellular Proteomics;2024-08

3. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

4. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors;Frontiers in Immunology;2024-06-05

5. Exploring salivary gene expression clusters: A bioinformatics approach for advanced diagnosis and prognosis in head and neck squamous cell carcinoma;Oral Oncology Reports;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3